Mutations in Bruton's tyrosine kinase impair IgA responses

被引:17
|
作者
Mitsuiki, Noriko [1 ]
Yang, Xi [2 ]
Bartol, Sophinus J. W. [3 ]
Grosserichter-Wagener, Christina [3 ]
Kosaka, Yoshiyuki [4 ]
Takada, Hidetoshi [5 ]
Imai, Kohsuke [1 ]
Kanegane, Hirokazu [2 ]
Mizutani, Shuki [1 ]
van der Burg, Mirjam [3 ]
van Zelm, Menno C. [3 ]
Ohara, Osamu [6 ,7 ]
Morio, Tomohiro [1 ]
机构
[1] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Pediat & Dev Biol, Bunkyo Ku, Tokyo 1138510, Japan
[2] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pediat, Toyama 930, Japan
[3] Univ Med Ctr, Erasmus MC, Dept Immunol, Rotterdam, Netherlands
[4] Hyogo Prefectural Childrens Hosp, Dept Hematol Oncol, Kobe, Hyogo, Japan
[5] Kyushu Univ, Grad Sch Med Sci, Dept Pediat, Fukuoka 812, Japan
[6] Kazusa DNA Res Inst, Dept Human Genome Technol, Chiba, Japan
[7] RIKEN Res Ctr Allergy & Immunol, Lab Immunogen, Kanagawa, Japan
基金
日本学术振兴会;
关键词
Bruton's tyrosine kinase; X-linked agammaglobulinemia; IgA deficiency; Class switch recombination; Somatic hypermutation; X-LINKED AGAMMAGLOBULINEMIA; B-CELL DEVELOPMENT; COMMON VARIABLE IMMUNODEFICIENCY; TRANSMEMBRANE ACTIVATOR; ANTIGEN-RECEPTOR; BTK; DEFICIENCY; IMMUNOGLOBULIN; HETEROZYGOTES; STIMULATION;
D O I
10.1007/s12185-015-1732-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency caused by mutations in Bruton's tyrosine kinase (BTK), and is characterized by markedly decreased numbers of blood B cells and an absence of all immunoglobulin isotypes. We performed whole exome sequencing in a male pediatric patient with dysgammaglobulinemia with IgA deficiency. Genetic analysis revealed a BTK missense mutation (Thr316Ala). To investigate whether a BTK mutation underlay this antibody deficiency with marked decrease of IgA in this patient, we performed functional analyses of B cells and phagocytes, and molecular analyses of somatic hypermutation and class switch recombination. The BTK missense mutation resulted in B cells with reduced BTK and high IgM expression. Equal proportions of CD19(low) and CD19(normal) fractions were observed, and both included na < ve and memory B cells. Calcium influx and phospholipase C gamma 2 phosphorylation upon IgM stimulation were marginally impaired in CD19(low), but not in CD19(+) B cells. Similar to XLA patients, IgA transcripts showed low SHM levels, whereas IgG transcripts were hardly affected. Our analyses suggest that the BTK mutation likely underlies the disease in this case, and that hypomorphic BTK mutations can result in normal circulating B cell numbers, but specifically impair IgA responses.
引用
收藏
页码:305 / 313
页数:9
相关论文
共 50 条
  • [1] Mutations in Bruton’s tyrosine kinase impair IgA responses
    Noriko Mitsuiki
    Xi Yang
    Sophinus J. W. Bartol
    Christina Grosserichter-Wagener
    Yoshiyuki Kosaka
    Hidetoshi Takada
    Kohsuke Imai
    Hirokazu Kanegane
    Shuki Mizutani
    Mirjam van der Burg
    Menno C. van Zelm
    Osamu Ohara
    Tomohiro Morio
    International Journal of Hematology, 2015, 101 : 305 - 313
  • [2] Bruton Tyrosine Kinase Gene Mutations in Argentina
    Danielian, Silvia
    El-Hakeh, Jazmin
    Basilico, Guillermo
    Oleastro, Matias
    Rosenzweig, Sergio
    Feldman, Guillermina
    Berozdnik, Liliana
    Galicchio, Miguel
    Gallardo, Angela
    Giraudi, Vera
    Liberatore, Diana
    Maria Rivas, Eva
    Zelazko, Marta
    HUMAN MUTATION, 2003, 21 (04)
  • [3] Bruton's Tyrosine Kinase Mutations in 8 Chinese Families with X-Linked Agammaglobulinemia
    Yip, Ka-Lun
    Chan, Siu-Yuen
    Ip, Wai-Kee
    Lau, Yu-Lung
    HUMAN MUTATION, 2000, 15 (04) : 385 - U66
  • [4] Mutations of Bruton's tyrosine kinase gene in Brazilian patients with X-linked agammaglobulinemia
    Ramalho, V. D.
    Oliveira Junior, E. B.
    Tani, S. M.
    Roxo Junior, P.
    Vilela, M. M. S.
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 2010, 43 (09) : 910 - 913
  • [5] Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases
    De Bondt, Mirre
    Renders, Janne
    Struyf, Sofie
    Hellings, Niels
    AUTOIMMUNITY REVIEWS, 2024, 23 (05)
  • [6] Inhibition of Bruton's tyrosine kinase as a novel therapeutic approach in multiple sclerosis
    Torke, Sebastian
    Weber, Martin S.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (10) : 1143 - 1150
  • [7] Role of Bruton's tyrosine kinase in B cells and malignancies
    Singh, Simar Pal
    Dammeijer, Floris
    Hendriks, Rudi W.
    MOLECULAR CANCER, 2018, 17
  • [8] The role of Bruton's tyrosine kinase in autoimmunity and implications for therapy
    Crofford, Leslie J.
    Nyhoff, Lindsay E.
    Sheehan, Jonathan H.
    Kendall, Peggy L.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2016, 12 (07) : 763 - 773
  • [9] Bruton's Tyrosine Kinase in Neutrophils Is Crucial for Host Defense against Klebsiella pneumoniae
    Liu, Zhe
    De Porto, Alexander P. N. A.
    De Beer, Regina
    Roelofs, Joris J. T. H.
    De Boer, Onno J.
    Florquin, Sandrine
    Van't Veer, Cornelis
    Hendriks, Rudi W.
    Van der Poll, Tom
    De Vos, Alex F.
    JOURNAL OF INNATE IMMUNITY, 2023, 15 (01) : 1 - 15
  • [10] Strategies to overcome resistance mutations of Bruton's tyrosine kinase inhibitor ibrutinib
    Liu, Linyi
    Shi, Bingyu
    Wang, Xiangqian
    Xiang, Hua
    FUTURE MEDICINAL CHEMISTRY, 2018, 10 (03) : 343 - 356